Literature DB >> 23317354

Premature death of TDP-43 (A315T) transgenic mice due to gastrointestinal complications prior to development of full neurological symptoms of amyotrophic lateral sclerosis.

Mohammad A Esmaeili1, Marzieh Panahi, Shilpi Yadav, Leah Hennings, Mahmoud Kiaei.   

Abstract

Abnormal distribution, modification and aggregation of transactivation response DNA-binding protein 43 (TDP-43) are the hallmarks of multiple neurodegenerative diseases, especially frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) and amyotrophic lateral sclerosis (ALS). Transgenic mouse lines overexpressing wild-type or mutant TDP-43 exhibit ALS-like symptom, motor abnormalities and early paralysis followed by death. Reports on lifespan and phenotypic behaviour in Prp-TDP-43 (A315T) vary, and these animals are not fully characterized. Although it has been proposed that the approximate 20% loss of motor neurons at end stage is responsible for the severe weakness and death in TDP-43 mice, this degree of neurologic damage appears insufficient to cause death. Hence we studied these mice to further characterize and determine the reason for the death. Our characterization of TDP-43 transgenic mice showed that these mice develop ALS-like symptoms that later become compounded by gastrointestinal (GI) complications that resulted in death. This is the first report of a set of pathological evidence in the GI track that is strong indicator for the cause of death of Prp-hTDP-43 (A315T) transgenic mice.
© 2012 The Authors. International Journal of Experimental Pathology © 2012 International Journal of Experimental Pathology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23317354      PMCID: PMC3575874          DOI: 10.1111/iep.12006

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  35 in total

1.  Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis.

Authors:  Mahmoud Kiaei; Khatuna Kipiani; Susanne Petri; Dong-Kug Choi; Junyu Chen; Noel Y Calingasan; M Flint Beal
Journal:  J Neurochem       Date:  2005-04       Impact factor: 5.372

2.  Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNA.

Authors:  Jiou Wang; Guilian Xu; Hilda H Slunt; Victoria Gonzales; Michael Coonfield; David Fromholt; Neal G Copeland; Nancy A Jenkins; David R Borchelt
Journal:  Neurobiol Dis       Date:  2005-07-19       Impact factor: 5.996

3.  Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Manuela Neumann; Deepak M Sampathu; Linda K Kwong; Adam C Truax; Matthew C Micsenyi; Thomas T Chou; Jennifer Bruce; Theresa Schuck; Murray Grossman; Christopher M Clark; Leo F McCluskey; Bruce L Miller; Eliezer Masliah; Ian R Mackenzie; Howard Feldman; Wolfgang Feiden; Hans A Kretzschmar; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2006-10-06       Impact factor: 47.728

Review 4.  Molecular biology of amyotrophic lateral sclerosis: insights from genetics.

Authors:  Piera Pasinelli; Robert H Brown
Journal:  Nat Rev Neurosci       Date:  2006-09       Impact factor: 34.870

5.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Tetsuaki Arai; Masato Hasegawa; Haruhiko Akiyama; Kenji Ikeda; Takashi Nonaka; Hiroshi Mori; David Mann; Kuniaki Tsuchiya; Mari Yoshida; Yoshio Hashizume; Tatsuro Oda
Journal:  Biochem Biophys Res Commun       Date:  2006-10-30       Impact factor: 3.575

6.  CLINICAL AND PATHOLOGICAL STUDIES OF AN HEREDITARY NEUROPATHY IN MICE (DYSTONIA MUSCULORUM).

Authors:  L W DUCHEN; S J STRICH; D S FALCONER
Journal:  Brain       Date:  1964-06       Impact factor: 13.501

7.  Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.

Authors:  Mahmoud Kiaei; Susanne Petri; Khatuna Kipiani; Gabrielle Gardian; Dong-Kug Choi; Junyu Chen; Noel Y Calingasan; Peter Schafer; George W Muller; Charles Stewart; Kenneth Hensley; M Flint Beal
Journal:  J Neurosci       Date:  2006-03-01       Impact factor: 6.167

8.  Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1.

Authors:  L I Bruijn; M K Houseweart; S Kato; K L Anderson; S D Anderson; E Ohama; A G Reaume; R W Scott; D W Cleveland
Journal:  Science       Date:  1998-09-18       Impact factor: 47.728

9.  TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis.

Authors:  Edor Kabashi; Paul N Valdmanis; Patrick Dion; Dan Spiegelman; Brendan J McConkey; Christine Vande Velde; Jean-Pierre Bouchard; Lucette Lacomblez; Ksenia Pochigaeva; Francois Salachas; Pierre-Francois Pradat; William Camu; Vincent Meininger; Nicolas Dupre; Guy A Rouleau
Journal:  Nat Genet       Date:  2008-03-30       Impact factor: 38.330

10.  HO-1 induction in motor cortex and intestinal dysfunction in TDP-43 A315T transgenic mice.

Authors:  Yansu Guo; Qian Wang; Kunxi Zhang; Ting An; Pengxiao Shi; Zhongyao Li; Weisong Duan; Chunyan Li
Journal:  Brain Res       Date:  2012-04-12       Impact factor: 3.252

View more
  38 in total

Review 1.  The bowel and beyond: the enteric nervous system in neurological disorders.

Authors:  Meenakshi Rao; Michael D Gershon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-07-20       Impact factor: 46.802

Review 2.  FTD and ALS--translating mouse studies into clinical trials.

Authors:  Lars M Ittner; Glenda M Halliday; Jillian J Kril; Jürgen Götz; John R Hodges; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2015-05-05       Impact factor: 42.937

Review 3.  Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders.

Authors:  Francisco Espejo-Porras; Fabiana Piscitelli; Roberta Verde; José A Ramos; Vincenzo Di Marzo; Eva de Lago; Javier Fernández-Ruiz
Journal:  J Neuroimmune Pharmacol       Date:  2015-03-29       Impact factor: 4.147

Review 4.  From animal models to human disease: a genetic approach for personalized medicine in ALS.

Authors:  Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré
Journal:  Acta Neuropathol Commun       Date:  2016-07-11       Impact factor: 7.801

5.  Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis.

Authors:  Francisco Espejo-Porras; Laura García-Toscano; Carmen Rodríguez-Cueto; Irene Santos-García; Eva de Lago; Javier Fernandez-Ruiz
Journal:  Br J Pharmacol       Date:  2018-05-06       Impact factor: 8.739

6.  Differential Neurotoxicity Related to Tetracycline Transactivator and TDP-43 Expression in Conditional TDP-43 Mouse Model of Frontotemporal Lobar Degeneration.

Authors:  L Kukreja; R Shahidehpour; G Kim; J Keegan; K R Sadleir; T Russell; J Csernansky; M Mesulam; R J Vassar; L Wang; H Dong; C Geula
Journal:  J Neurosci       Date:  2018-05-28       Impact factor: 6.167

Review 7.  From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis.

Authors:  Aziza Rashed Alrafiah
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

Review 8.  Amyotrophic lateral sclerosis--a model of corticofugal axonal spread.

Authors:  Heiko Braak; Johannes Brettschneider; Albert C Ludolph; Virginia M Lee; John Q Trojanowski; Kelly Del Tredici
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

Review 9.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

10.  Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS.

Authors:  Anna Emde; Chen Eitan; Lee-Loung Liou; Ryan T Libby; Natali Rivkin; Iddo Magen; Irit Reichenstein; Hagar Oppenheim; Raya Eilam; Aurelio Silvestroni; Betty Alajajian; Iddo Z Ben-Dov; Julianne Aebischer; Alon Savidor; Yishai Levin; Robert Sons; Scott M Hammond; John M Ravits; Thomas Möller; Eran Hornstein
Journal:  EMBO J       Date:  2015-09-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.